

# **Patient Centered Medical Home (PCMH) Pharmacist Collaborative Practice Agreement**

**Nebraska Medicine  
988138 Nebraska Medical Center  
Omaha, NE 68198-8138  
800-922-0000**

**Effective: October 1<sup>st</sup>, 2021  
Expiration: September 30<sup>th</sup>, 2023**

# Table of Contents

1.0 Introduction .....	3
1.1 Background.....	3
1.2 Authority, Scope and Purpose .....	3
1.3 Collaborating Professionals .....	4
1.4 Patients.....	4
1.5 Goals .....	5
2.0 Management.....	5
2.1 Clinical Practice Guidelines .....	5
2.2 Management Guides .....	6
2.3 Procedures.....	6
3.0 Organization .....	7
3.1 Provider Eligibility .....	7
3.2 Training/Education .....	7
3.3 Documentation and Communication .....	7
3.4 Period of Validity.....	7
3.5 Amendment.....	7
4.0 Signatures of Approval.....	7
APPENDIX: Clinical Practice Guidelines	

# 1.0 Introduction

## 1.1 Background

- According to Nebraska State Statute (128-013) pharmacists may practice pharmaceutical care under Collaborative Practice Agreement with individual providers. Pharmaceutical care is defined as the process through which the pharmacist works in concert with the patients and his or her caregiver, physician, or other professionals in managing and monitoring drug therapy to produce specific therapeutic outcomes.
- It is the intent of this document to authorize the pharmacist at the Nebraska Medicine Patient Centered Medical Home (PCMH) clinics to practice collaboratively with physicians and healthcare providers to provide comprehensive patient care and associated disease state management.

## 1.2 Authority and Purpose

- Nebraska Medicine is committed to providing high quality care in the most affordable, efficient way. Pharmacists at the PCMH clinics are integral part of multi-disciplinary teams who function as physician extenders to achieve these goals and to provide excellent patient care. The purpose of this agreement is to enhance collaborative patient care and optimize patient outcomes
- Per this agreement the pharmacists named herein, who hold an active license to practice issued by Nebraska, are authorized to manage and/or treat patients pursuant to the parameters outlined in this agreement. This authority follows the laws and regulations of Nebraska.
- This agreement authorizes the pharmacist to:
  - Conduct a comprehensive medication review and assessment
  - Determine the indication for, effectiveness and safety of, and adherence to medication therapy
  - Perform, administer, monitor, and evaluate vitals, rating scales, risk scores, and other relevant objective data
  - Select, initiate, modify, or discontinue treatment related to the disease states and medication therapies in accordance with established practice guidelines (see Appendix)
  - Change medication therapy to improve efficacy, ensure availability, decrease toxicity, decrease cost, or improve adherence of medication when necessary
  - Order and evaluate laboratory tests relevant to medication monitoring or disease management according to guidelines
  - Monitor and follow-up on medication therapies and related disease states as per guidelines
  - Refer and coordinate care to other health care professionals
  - Refill medications pertinent to the disease state or medications being managed
  - Order immunizations per guidelines

- Educate patients concerning disease states and self-monitoring methods, medication education and adherence, and life-style modifications
- Document the clinic visits/encounters and education in medical records
- This agreement authorizes the pharmacist to manage Care Gaps and initiate Population Health Management to improve patients' care and outcome. Authority is given to order medications, laboratory tests, immunizations, screening exam (diabetes ophthalmology), and others as per PCMH initiatives
- This agreement provides the authority and scope to the Pharmacy Residents and Fellows rotating in the PCMH clinics. PCMH Pharmacists will supervise Pharmacy Residents' activities.

### 1.3 Collaborating Professionals

- Medicine Providers at the following practice sites/clinics:
  - Brentwood Health Center
  - Chalco Health Center
  - Eagle Run Health Center
  - Elkhorn Health Center
  - Family Medicine Clinic at Bellevue Health Center
  - Family Medicine Clinic at Durham Outpatient Center
  - Fontenelle Health Center
  - Home Instead Center for Successful Aging (HISCA)
  - Internal Medicine Clinic at Durham Outpatient Center
  - Internal Medicine Clinic at Village Pointe Health Center
  - Midtown Health Center
  - Old Market Health Center
  - Primary Care Clinic at Oakview Health Center

### 1.4 Patients

- Patients whose therapy may be managed pursuant to this agreement are currently receiving care by a provider at Nebraska Medicine PCMH clinics.
- Patients may be identified by the following methods:
  - Provider Referral
    - The provider may refer any patient to whom they determine pharmacy services would be beneficial
  - Usual Pharmacist's Service
    - A provider or patient specific referral is not needed for the pharmacist to initiate the following services
      - Medication Reconciliation
      - Formulary or Therapeutic Interchange
      - Medication management due to availability, cost, efficacy, and toxicity
      - Medication Access
      - Care Gap management

- Pharmacotherapy consultation
- Patient Self-Referral
  - Any patient that would like to receive pharmacy services
- PCMH Initiatives
  - A referral is not needed for any of PCMH initiatives
  - Patients identified per specific projects, pathways, database/dashboard, or other resources
- Population Management
  - A referral is not needed for any projects that are part of Population Health management
    - Reports from medical records are utilized to initiate pharmacy services per PCMH or clinic initiative

## 1.5 Goals

- To optimize drug therapy
- To reach clinical health targets and quality metrics
- To improve patient adherence and medication access
- To decrease preventable emergency room visits and hospital readmissions
- To improve the health of patients and their quality of life

## 2.0 Management

### 2.1 Clinical Practice Guidelines

- Pharmacist will utilize most current and up to date guidelines and literatures to guide medication management for specific disease states (See Appendix)
- Disease states and its associated medication therapies commonly managed by pharmacists are listed below. This is not an exhaustive list

Disease State or Service*	Medication Therapies
Comprehensive Medication Review and Management	•Based on disease states
Anticoagulation	•All anticoagulants
Diabetes**	•All oral, injectable, and inhaled antidiabetic agents
Hypertension**	•All BP modifying agents
Cholesterol**	•All cholesterol modifying agents
Asthma	•Inhaled and oral agents for Asthma
COPD	•Inhaled and oral agents for COPD
GERD	•Antacids, H2 blockers, PPIs

Hepatitis C	•All agents
Hypothyroidism	•All thyroid replacement agents
Osteoarthritis	•Oral and topical agents for OA
Osteoporosis	•All agents for osteoporosis
Anxiety and Depression	•All non-controlled agents for anxiety and depression
Immunization***	•All vaccinations
Smoking Cessation	• All pharmacologic agents
PrEP	• PrEP agents
Others: Specific medication management referred by the provider	•Per provider

\*Pharmacist will follow the most current published version of the guidelines and use clinical judgment.

\*\*Referral for diabetes includes management of diabetes, blood pressure, and cholesterol medications. It also addressed diabetes complications and CV risk reduction

\*\*\*Immunization management for chronic disease states

## 2.2 Management Guide

- Specific management guides based on current guidelines, evidence, and Nebraska Medicine policies are developed to assist with management: Anticoagulation, COPD, Diabetes, Hypertension, PrEP, Smoking Cessation, Hepatitis C (See Attachments)

## 2.3 Procedure

- As stated above, pharmacist is authorized to select, initiate, modify, or discontinue medications as part of management. Authority is also given to order laboratory tests or screening procedures for management or monitoring purpose.
- Prescriptions, immunizations, laboratory tests will be ordered under provider's name. Refills are authorized under the providers as deemed appropriate
- Consultation with the collaborating physicians or their designated back-up either on-site, by pager, telephone, or electronically when consultation is needed for any reason
- In the case of a severe event or toxicity, the patient will be immediately referred to a provider or their designated back-up involved in the CPA. The pharmacist

shall contact the provider via face-to-face communication; however, electronic, or telephonic communication is acceptable for non-emergent cases

- The provider has the authority to override this agreement if such action is deemed necessary or appropriate for a specific patient

## **3.0 Organization**

### **3.1 Provider Eligibility**

- Physicians and pharmacists of The Nebraska Medicine in PCMH clinics listed in this agreement are considered qualified providers to participate in patient-care activities related to this agreement.
- All providers must be licensed in good standing with their respective board and follow established standards for entering and managing a collaborative practice agreement.

### **3.2 Training/Education**

- All listed parties will receive sufficient training and education for their role.
- All listed parties are expected to maintain up-to-date competencies and knowledge of current guidelines for disease states covered under this agreement.

### **3.3 Documentation and Communication**

- Pharmacists will document interventions in the patient's electronic medical record after the patient encounter. Pharmacists will electronically route a note to the provider as deemed appropriate

### **3.4 Period of Validity**

- This agreement is valid for up to 2 years following signatures of all parties.

### **3.5 Amendment**

- This agreement may be amended prior to the 2-year expiration date.
- Amendments must include detailed changes to this agreement. Amendments must be provided to both parties prior to implementation and signed by Medical Director

## **4.0 Signatures of Approval**

This agreement will be in effect for two years unless rescinded earlier in writing by either party. Any addendums to this agreement or modification to the CPA shall require signature approval from Medical Director.


When new Pharmacists join participating Nebraska Medicine PCMH clinics during the agreement cycle, new Pharmacists will be required to sign the CPA and the CPA will be submitted to the Nebraska Board of Pharmacy.

When new providers join participating Nebraska Medicine PCMH clinics during the agreement cycle, new providers will be informed of this agreement and all medication changes will be ordered under the clinic's Medical Director until the agreement is reviewed and new provider signatures are obtained.

### The Nebraska Medicine PCMH Medical Director

The PCMH Medical Director/Primary Care Clinical Program Chair is responsible for periodically evaluating the clinical services, reviewing the above agreement, and reviewing quality data or metrics.

Primary Care Clinical Program Chair:

  
\_\_\_\_\_  
Andrew J. Vasey, MD

Effective October 1, 2021

### The Nebraska Medicine PCMH Ambulatory Care Pharmacist Signatures

Emily Shin, RP Emily Shin

Chia (Lily) Chang, RP Chia (Lily) Chang

Canice Coan, RP Canice Coan

Kristen Cook, RP Kristen Cook

Anthony Donovan, RP Anthony Donovan

Logan Franck, RP Logan Franck


Angie Hawkins, RP Angie Hawkins

Karen Knoell, RP Karen Knoell

Drew Prescott, RP Drew Prescott



Natalie Tiefenthaler, RP Natalie Tiefenthaler

Kimberlee Thompson, RP 

Caressa Trueman, RP Caressa A. Trueman

Sarah Sheehy, RP Sarah Sheehy, PharmD

Phil Van De Velde, RP Phil Van De Velde

Carrie Nixon, RP Carrie Nixon

Nolan Persson, RP Nolan Persson

Sara Bisanz, RP Sara Bisanz, PharmD

Angie Kinney, RP Angie Kinney

**The Nebraska Medical Center Providers:**

As an authorizing/participating physician in this collaborate practice agreement, participating I will review the activities of the PCMH Ambulatory Care Pharmacists at Nebraska Medicine while my patients are being managed under this agreement. This authorization shall remain in effect for any patients I refer to their management until they are discharged back to my care. This agreement is rescinded or until, or after two years when the agreement must be re-reviewed.

**Family Medicine Clinic at Bellevue Health Center**

**Authorized Providers:**

<u>Ivan Abdouch, MD</u> Ivan Abdouch, MD	<u>9/29/2021</u> Date
<u>Tammy Burke</u> Tammy Burke, MD	<u>9/21/2021</u> Date
<u>Jayme Clara, APRN</u> <u>J. M.</u> Toby Free, MD	<u>Date</u> <u>9/30/2021</u> Date
<u>Aaron Lanik</u> Aaron Lanik, MD	<u>9/17/2021</u> Date
<u>Jeffery D Harrison</u> Jeffery Harrison, MD	<u>9/17/2021</u> Date
<u>Natalie Lynch, DO</u> Natalie Lynch, DO	<u>9/20/2021</u> Date
<u>Emily Hill Bowman, MD</u> Emily Hill-Bowman, MD	<u>9/20/2021</u> Date
<u>Jeremy King, DO</u> Jeremy King, DO	<u>9/17/2021</u> Date
<u>David O'Dell, MD</u> David O'Dell, MD	<u>9/17/2021</u> Date
<u>Robert Schwab, MD</u> Robert Schwab, MD	<u>9/28/2021</u> Date
<u>James Simmons, MD</u> James Simmons, MD	<u>9/20/2021</u> Date
<u>Amber Tyler, MD</u> Amber Tyler, MD	<u>9/17/2021</u> Date

**Family Medicine Clinic at Bellevue Health Center**

**Authorized Providers:**

Jeffrey Akerson, MD 9/17/2021  
Date

Patrick Anderl, MD 9/17/2021  
Date

Tara Burleigh, MD 9/17/2021  
Date

Keely Hagerty, APRN 9/17/2021  
Date

Monty Mathews 9/17/2021  
Date

Kara Markin 9/28/2021  
Date

T. Jason Meredith, MD 9/17/2021  
Date

Cory Rohlfson, MD 9/17/2021  
Date

Tesia Winter 9/19/2021  
Date

**Brentwood Village**

**Authorized Providers:**

Brent Crouse, MD  
Brent Crouse, MD

9/18/2021

Date

Emily Hill Bowman, MD  
Emily Hill Bowman, MD

9/20/2021

Date

Susan Schwerdtfeger, MD  
Susan Schwerdtfeger, MD

9/17/2021

Date

Mary Couture, PA-C  
Mary Couture, PA-C

9/20/2021

Date

Kimberly Meyer, PA-C  
Kimberly Meyer, PA-C

9/17/2021

Date

**Chalco**

**Authorized Providers:**

Brynn Lastovica  
Brynn Lastovica, MD

9/17/2021

Date

Alberto Marcelin, MD  
Alberto Marcelin, MD

9/27/2021

Date

Briahna Carlson, APRN-NP  
Briahna Carlson, APRN-NP

9/20/2021

Date

Julie Nieveen, APRN-NP  
Julie Nieveen, APRN-NP

9/20/2021

Date

**Clarkson Family Medicine**

**Authorized Providers:**

Dale Agner, MD  
Dale Agner, MD

9/24/2021  
Date

Sarah Howard, MD  
Sarah Howard, MD

9/17/2021  
Date

Amy Jespersen, MD  
Amy Jespersen, MD

9/17/2021  
Date

Scott M McPherson MD  
Scott McPherson, MD

9/20/2021  
Date

Leslie Veskrna, MD  
Leslie Veskrna, MD

9/17/2021  
Date

**Family Medicine Clinic at Durham Outpatient Center**

**Authorized Providers:**

Hannah Christiansen 9/20/2021  
Hannah Christiansen, MD Date

-----  
Patrick Cronican, MD Date

Susan Evans, MD 9/24/2021  
Susan Evans, MD Date

David Harnisch, MD 9/17/2021  
David Harnisch, MD Date

Kimberly Jarzynka, MD 9/20/2021  
Kimberly Jarzynka, MD Date

Christopher Jensen, MD 9/17/2021  
Christopher Jensen, MD Date

Neil Kalsi, MD 9/19/2021  
Neil Kalsi, MD Date

Jessica Kapple PA-C 9/17/2021  
Jessica Kapple PA-C Date

Birgit Khandalavala 9/20/2021  
Birgit Khandalavala, MD Date

Mindy Lacey, MD 9/20/2021  
Mindy Lacey, MD Date

Timothy Malloy, MD 9/17/2021  
Timothy Malloy, MD Date

Monty Mathews 9/17/2021  
Monty Mathews, MD Date

Michael Sitorius, M.D.  
Michael Sitorius, MD

9/17/2021  
Date

John Smith, MD  
John Smith, MD

9/20/2021  
Date

Douglas Wheatley, MD  
Douglas Wheatley, MD

9/17/2021  
Date

Susan Wollenburg, PA-C  
Susan Wollenburg, PA-C

9/17/2021  
Date

**Primary Care Clinic at Oakview Health Center**

**Authorized Providers:**

Elisabeth Backer, MD  
Elisabeth Backer, MD

9/19/2021  
Date

Zachary J Genant, MD  
Zachary Genant, MD

9/24/2021  
Date

Jennifer Liu  
Jennifer Liu, MD

9/20/2021  
Date

Linda Demeulmeester PA-C  
Linda Demeulmeester PA-C

9/17/2021  
Date


















Vanessa Potter PA-C  
Vanessa Potter PA-C

9/20/2021  
Date



**Durham Outpatient Center Internal Medicine Clinic**

**Authorized Providers:**

 _____	9/27/2021 _____
Kurt Andree, PA-C	Date
 _____	9/20/2021 _____
Laura Boon, APRN-NP	Date
 _____	9/27/2021 _____
Rod Carlson, PA-C	Date
 _____	9/17/2021 _____
Devin Nickol, MD	Date
 _____	9/17/2021 _____
Nathan Anderson, MD	Date
 _____	9/17/2021 _____
David O'Dell, MD	Date
 _____	9/17/2021 _____
Stephen Mohring, MD	Date
 _____	9/17/2021 _____
Carrie Hoarty, MD	Date
 _____	9/28/2021 _____
Mel Huber, APRN-NP	Date
 _____	9/17/2021 _____
Lydia Kang, MD	Date
 _____	9/17/2021 _____
Scott Neumeister, MD	Date
 _____	9/17/2021 _____
Andrew Vasey, MD	Date
 _____	9/17/2021 _____
Rae Witt, MD	Date
 _____	9/17/2021 _____
Chelsea Navarrette, MD	Date
 _____	9/17/2021 _____
Melissa Teply, MD	Date
 _____	9/17/2021 _____
Mary Gallagher-Jansen, MD	Date
 _____	9/17/2021 _____

Regan Taylor, MD






Date

**Eagle Run Clinic**

**Authorized Providers:**

<u>Andrew Camamo, DO</u> Andrew Camamo, DO	<u>9/17/2021</u> Date
<u>Nicole Goliber, PA</u> Nicole Goliber, PA	<u>9/20/2021</u> Date
<u>Emily Hill, APRN</u> Emily Hill, APRN	<u>9/17/2021</u> Date
<u>Brandon J. Miller, MD</u> Brandon J. Miller, MD	<u>9/17/2021</u> Date
<u>Cory Rohlfson, MD</u> Cory Rohlfson, MD	<u>9/17/2021</u> Date
<u>Megan Willet</u> Megan Willet, MD	<u>9/17/2021</u> Date
<u>Tesia Winter</u> Tesia Winter, DO	<u>9/19/2021</u> Date
<u>Darby Luckey, DO</u> Darby Luckey, MD	<u>9/17/2021</u> Date

**Elkhorn Clinic**

 _____	9/20/2021 _____
Jason Patera, MD  _____	Date 9/24/2021 _____
Riki Rutz, PA  _____	Date 9/21/2021 _____
Rebecca Ellsworth, PA  _____	Date 9/22/2021 _____
Chad Moes, MD  _____	Date 9/20/2021 _____
Amber Brown-Keebler, MD	Date

**Fontenelle Clinic**

**Authorized Providers:**

<u>Jennifer Parker, MD</u> Jennifer Parker, MD	<u>9/20/2021</u> Date
<u>Daniel Jeffery, MD</u> Daniel Jeffery, MD	<u>9/20/2021</u> Date
<u>Sarah Smith, MD</u> Sarah Smith, MD	<u>9/23/2021</u> Date
<u>Rachel Johnson, MD</u> Rachel Johnson, MD	<u>9/27/2021</u> Date
<u>William Hay, MD</u> William Hay, MD	<u>9/21/2021</u> Date
<u>Andrea Jones</u> Andrea Jones, MD	<u>9/27/2021</u> Date
<u>Susan Hollins, MD</u> Susan Hollins, MD	<u>9/29/2021</u> Date
<u>Eamon Maloney, MD</u> Eamon Maloney, MD	<u>9/28/2021</u> Date
<u>Laura Loukota, APRN</u> Laura Loukota, APRN	<u>9/20/2021</u> Date
<u>Peggy Schneider</u> Peg Schneider, PA	<u>9/20/2021</u> Date

HICSA Geriatrics

Authorized Providers:

<u>Karina Bishop, MD</u> Karina Bishop, MD	<u>9/20/2021</u> Date
<u>Mandy Byers</u> Mandy Byers, MD	<u>9/20/2021</u> Date
<u>Alfred Fisher, MD</u> Alfred Fisher, MD	<u>9/20/2021</u> Date
<u>Kelly Godfrey, APRN</u> Kelly Godfrey, APRN	<u>9/20/2021</u> Date
<u>Elizabeth Harlow</u> Elizabeth Harlow, MD	<u>9/20/2021</u> Date
<u>Joseph Hejkal, MD</u> Joseph Hejkal, MD	<u>9/20/2021</u> Date
<u>Jessie Jenkins, MD</u> Jessie Jenkins, MD	<u>9/20/2021</u> Date
<u>William Lyons, MD</u> William Lyons, MD	<u>9/20/2021</u> Date
<u>Natalie Manley, MD</u> Natalie Manley, MD	<u>9/20/2021</u> Date
<u>Tonya Mcleay, APRN</u> Tonya Mcleay, APRN	<u>9/23/2021</u> Date
<u>Jane Potter, MD</u> Jane Potter, MD	<u>9/20/2021</u> Date
<u>Sara Wolfson, APRN</u> Sara Wolfson, APRN	<u>9/20/2021</u> Date
<u>Brandi Flagg, MD</u> Brandi Flagg, MD	<u>9/20/2021</u> Date
<u>Cassandra Wehling, MD</u> Cassandra Wehling, MD	<u>9/20/2021</u> Date
<u>Katherine Maliszewski, MD</u> Katherine Maliszewski, MD	<u>9/21/2021</u> Date

**Midtown Clinic**

**Authorized Providers:**

<u>Daniel Jeffery, MD</u> Daniel Jeffery, MD	<u>9/20/2021</u> Date
<u>Stephen Mohring, MD</u> Stephen Mohring, MD	<u>9/20/2021</u> Date
<u>Scott Neumeister, MD</u> Scott Neumeister, MD	<u>9/20/2021</u> Date
<u>Jennifer Parker, MD</u> Jennifer Parker, MD	<u>9/20/2021</u> Date
<u>Regan Taylor, MD</u> Regan Taylor, MD	<u>9/20/2021</u> Date
<u>Andrew Vasey</u> Andrew Vasey, MD	<u>9/20/2021</u> Date
<u>Chad Vokoun</u> Chad Vokoun, MD	<u>9/21/2021</u> Date
<u>Carrie A B Hoarty, MD</u> Carrie A B Hoarty, MD	<u>9/20/2021</u> Date
<u>Jennilee Luedders, MD</u> Jennilee Luedders, MD	<u>9/20/2021</u> Date

**Village Pointe Internal Medicine Clinic**

**Authorized Providers:**

Joel Armitage, MD 9/20/2021  
Date

Michelle Johnson, MD 9/20/2021  
Date

Nancye Hasiak, APRN-C 9/28/2021  
Date

Stephanie Hartman, MD 9/20/2021  
Date

Kara Markin, MD 9/20/2021  
Date

Urmila Mukherjee, MD 9/21/2021  
Date

**Nebraska Medicine-Pulmonary (Anti-coagulation CPA only)**

Tammy Wichman MD 9/20/2021  
Date



## Appendix

### **Anticoagulation**

- Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: CHEST Evidence-Based Clinical Practice Guidelines. 2012  
[https://journal.chestnet.org/article/S0012-3692\(12\)60114-7/pdf?code=chest-site](https://journal.chestnet.org/article/S0012-3692(12)60114-7/pdf?code=chest-site)
  - Updated Antithrombotic Therapy and Prevention of Thrombosis: CHEST Evidence-Based Clinical Practice Guidelines. 2016. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016;149(2):315-352  
[https://journal.chestnet.org/article/S0012-3692\(15\)00335-9/pdf](https://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf)
- American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism.  
<http://www.bloodadvances.org/collection/clinical-guidelines%20?sso-checked=true>
- 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation. Circulation 2014;130:e199-e267  
<https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000041>
  - 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation. Circulation. 2019;140:e125–e151  
<https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000665>
  - Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014;82:716-724  
<http://n.neurology.org/content/neurology/82/8/716.full.pdf>
  - Updated Antithrombotic Therapy for Atrial Fibrillation: CHEST Evidence-Based Clinical Practice Guidelines. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest 2018.  
[https://journal.chestnet.org/article/S0012-3692\(18\)32244-X/pdf](https://journal.chestnet.org/article/S0012-3692(18)32244-X/pdf)
  - 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Circulation. 2014;130:e199–e267  
<https://ahajournals.org/doi/pdf/10.1161/CIR.0000000000000041>
  - 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines  
<https://www.ahajournals.org/doi/10.1161/CIR.0000000000000923>

### **Asthma**

- 2020 Focused Update to the Asthma Management Guidelines. National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group  
[https://www.nhlbi.nih.gov/sites/default/files/media/docs/NAEPPCC%20Guidelines%20Update%20Summary\\_May2020.pdf](https://www.nhlbi.nih.gov/sites/default/files/media/docs/NAEPPCC%20Guidelines%20Update%20Summary_May2020.pdf)
- 2007 National Asthma Education and Prevention Program Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma

<https://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf>

- 2018 GINA Report, Global Strategy for Asthma Management and Prevention  
<https://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/>

### **Cholesterol**

- 2013 American College of Cardiology/ American Heart Association (ACC/AHA) Guideline on Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, NCEP ATP-IV. Circulation 2014;129(supl 2): S1-S45  
<https://www.ahajournals.org/doi/pdf/10.1161/01.cir.0000437738.63853.7a?papetoc=>

2018 AHA/ACC Guideline on the Management of Blood Cholesterol.

- <https://www.acc.org/guidelines/hubs/blood-cholesterol>

### **Comprehensive Medication Management**

- The Patient-Centered Medical Home: Integrating Comprehensive Medication Management to Optimize Patient Outcomes. Resource Guide. Second Edition, June 2012.  
<https://www.pcpcc.org/sites/default/files/media/medmanagement.pdf>
- Collaborative Drug Therapy Management and Comprehensive Medication Management 2015. ACCP White Paper. American College of Clinical Pharmacy. Pharmacotherapy 2015;35(4):e39-e50.  
<https://www.accp.com/docs/positions/whitePapers/CDTM%20CMM%202015%20Final.pdf>

- Beers Update 2019

[https://depts.washington.edu/mbwc/content/page-files/BeersCriteria\\_2019\\_AGS\\_.pdf](https://depts.washington.edu/mbwc/content/page-files/BeersCriteria_2019_AGS_.pdf)

### **COPD**

- 2020 American Thoracic Society Clinical Practice Guideline. Pharmacologic Management of Chronic Obstructive Pulmonary Disease  
<https://www.atsjournals.org/doi/pdf/10.1164/rccm.202003-0625ST>
- 
- 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Executive Summary: Global Strategy for Diagnosis, Management, and Prevention of COPD.  
[https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20\\_WMV.pdf](https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf)

### **Diabetes**

- 2021 American Diabetes Association (ADA) Clinical Practice Guidelines  
[https://care.diabetesjournals.org/content/44/Supplement\\_1](https://care.diabetesjournals.org/content/44/Supplement_1)
- ACC Expert Consensus Pathway on CV Risk Reduction in Diabetes Patients  
<https://www.jacc.org/doi/pdf/10.1016/j.jacc.2020.05.037>
- American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE) “Consensus Statement on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary.  
[https://pro.ace.com/pdfs/diabetes/AACE\\_2019\\_Diabetes\\_Algorithm\\_03.2021.pdf](https://pro.ace.com/pdfs/diabetes/AACE_2019_Diabetes_Algorithm_03.2021.pdf)

## **GI**

- ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol 2017;10:1-26  
<http://gi.org/wp-content/uploads/2017/06/ajg2017154a.pdf>
- ACG Guidelines for the Diagnosis and Management of Gastroesophageal reflux Disease. Am J Gastroenterol 2013;108:308-328  
[http://gi.org/wp-content/uploads/2013/10/ACG\\_Guideline\\_GERD\\_March\\_2013\\_plus\\_corrigendum.pdf](http://gi.org/wp-content/uploads/2013/10/ACG_Guideline_GERD_March_2013_plus_corrigendum.pdf)  
<http://gi.org/wp-content/uploads/2018/04/ACG-GERD-Guideline-Summary.pdf>
- ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017; 112:212-238  
<http://gi.org/wp-content/uploads/2017/02/ACGManagementofHpyloriGuideline2017.pdf>
- ACG Guidelines for Prevention of NSAID-Related Ulcer Complications. Am J Gastroenterol 2009; 104:728-738  
<http://s3.gi.org/physicians/guidelines/NSAIDJournalPublicationFebruary2009.pdf>

## **Heart Failure**

- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America  
<https://www.ahajournals.org/doi/10.1161/cir.000000000000509>
- 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. J Am Coll Cardiol 2013;62:1495-539  
<https://www.acc.org/~media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Tools%20and%20Practice%20Support/Quality%20Programs/Heart%20Failure%20Roundtable%202016/Heart%20Failure%20Guidelines/HFG%203%202013%20ACCFAHA%20Guideline.pdf>
- 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2016;134: e282-e293  
<https://www.ahajournals.org/doi/full/10.1161/CIR.000000000000435>

## **Hepatitis C**

- HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. American Association for the Study of Liver Diseases (AASLD) & Infectious Diseases Society of America (ISDA). <https://www.hcvguidelines.org>  
[https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/AASLD-IDSA\\_HCVGuidance\\_January\\_21\\_2021.pdf](https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/AASLD-IDSA_HCVGuidance_January_21_2021.pdf)
- HCV: Hepatitis C Virus. ISDA. <https://www.idsociety.org/public-health/hepatitis-c/hcv-hepatitis-c-virus/>

## **Hypertension**

- 2020 International Society of Hypertension Global Hypertension Practice Guidelines  
<https://www.ahajournals.org/doi/epub/10.1161/HYPERTENSIONAHA.120.15026>

- Evidence-Based Guideline for the Management of High Blood Pressure in Adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)  
<https://jamanetwork.com/journals/jama/fullarticle/1791497>
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults  
<http://www.onlinejacc.org/content/early/2017/11/04/j.jacc.2017.11.006>
- 2019 American Diabetes Association (ADA) Clinical Practice Guidelines.  
[https://care.diabetesjournals.org/content/42/Supplement\\_1](https://care.diabetesjournals.org/content/42/Supplement_1)
- KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease  
[http://www.kdigo.org/clinical\\_practice\\_guidelines/pdf/CKD/KDIGO\\_2012\\_CKD\\_GL.pdf](http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf)

### **Hypothyroidism**

- ATA/AACE: Clinical Practice Guidelines For Hypothyroidism In Adults  
<https://www.aace.com/files/final-file-hypo-guidelines.pdf>

### **Immunizations**

- Centers for Disease Control (CDC), Advisory Committee on Immunization Practices (ACIP) 2021  
<https://www.immunize.org/cdc/schedules/>

### **Ischemic Heart Disease**

- ACC/AHA/AATS/PCNA/SCAI/STS Focused Update. 2014 ACC/AHA/ATS/PCNA/SCAI/STS focused Update of the Guideline for the Diagnosis and Management of Patient with Stable Ischemic Heart Disease. Circulation 2014;130:1749-1767  
<https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000095>
- 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease. Circulation 2012;126:e354-e471.  
<https://www.ahajournals.org/doi/abs/10.1161/CIR.0b013e318277d6a0>
- ACC/AHA Focused Update. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease. Circulation 2016;134:e12303155  
<https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000404?sid=792a47ea-2a99-4c7c-a699-441feb841745>

### **Osteoarthritis**

- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee  
<https://www.rheumatology.org/Portals/0/Files/Osteoarthritis-Guideline-Early-View-2019.pdf>

### **Osteoporosis**

- American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 Update  
<https://www.sciencedirect.com/science/article/pii/S1530891X20428277>

- 2016 AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. Endocrine Practice 22 (Suppl 4): 1-42  
<https://journals.aace.com/doi/pdf/10.4158/EP161435.GL>

- 2017 Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women. A Clinical Practice Guideline Update from the American College of Physicians  
<http://annals.org/aim/fullarticle/2625385/treatment-low-bone-density-osteoporosis-prevent-fractures-men-women-clinical>

### **PrEP**

- CDC: Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men. MMWR 2011;60(03): 65-68  
<https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a1.htm>
- CDC: Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults  
<https://www.cdc.gov/Mmwr/preview/mmwrhtml/mm6131a2.htm>
- CDC: Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for Injecting Drug Users  
[https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6223a2.htm?s\\_cid=mm6223a2\\_e](https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6223a2.htm?s_cid=mm6223a2_e)

### **Psychiatry**

- Practice Guideline for the Treatment of Patients with Panic Disorder. American Psychiatric Association 2009  
[http://psychiatryonline.org/pb/assets/raw/sitewide/practice\\_guidelines/guidelines/panicdisorder.pdf](http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf)
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision. The World Journal of Biological Psychiatry 2008;9(4): 248-312  
[http://www.wfsbp.org/fileadmin/user\\_upload/Treatment\\_Guidelines/Guidelines\\_Anxiety\\_revision.pdf](http://www.wfsbp.org/fileadmin/user_upload/Treatment_Guidelines/Guidelines_Anxiety_revision.pdf)
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice. 2012;16:77-84  
[https://www.wfsbp.org/fileadmin/user\\_upload/Treatment\\_Guidelines/Bandelow\\_et\\_al\\_01.pdf](https://www.wfsbp.org/fileadmin/user_upload/Treatment_Guidelines/Bandelow_et_al_01.pdf)
- AGS: Practice Guideline for the Treatment of Patient with Major Depressive Disorder. Third Edition.  
[http://psychiatryonline.org/pb/assets/raw/sitewide/practice\\_guidelines/guidelines/mdd.pdf](http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf)

### **Smoking Cessation**

- Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Executive Summary: Global Strategy for Diagnosis, Management, and Prevention of COPD. 2019  
[https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-POCKET-GUIDE-FINAL\\_WMS.pdf](https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-POCKET-GUIDE-FINAL_WMS.pdf)
- Treating Tobacco Use and Dependence: 2008 Update. Clinic Practice Guideline, US Department of Health and Human Services

<https://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/tobacco/clinicians/update/index.html>

- Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline. 2020.  
<https://www.atsjournals.org/doi/pdf/10.1164/rccm.202005-1982ST>

### **Stroke**

- Guidelines for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack. A Guideline for Healthcare Professionals from the American Heart Association /American Stroke Association. Stroke 2014;45:2160-2236

<https://www.ahajournals.org/doi/abs/10.1161/str.0000000000000024>

- Guidelines for the Prevention of Stroke in Women. A Statement for Healthcare Professionals from the American Heart Association//American Stroke Association. Stroke 2014;45:1545-1588

<https://www.ahajournals.org/doi/abs/10.1161/01.str.0000442009.06663.48>